AVTXAvalo Therapeutics Inc
$13.10
$0.51
(3.75%)
Closed $13.10
$0.26
(1.99%)
After Hours
Reported EarningsMay 13
Mkt Cap$688.61M
Vol1.76M
Fundamentals
Mkt Cap
$688.61M
Volume
-
52W High
$24.27
52W Low
$4.20
PE Ratio
-2.25
Avg. Volume
2.93M
EPS (Annual)
-$5.84
Rev/Employee
$1,787.88
Earnings
May 13
Biotech Stocks To Add to Your Watchlist - May 6th
Danaher, Avalo Therapeutics, Vertex Pharmaceuticals, United Therapeutics, argenex, ImmunityBio, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that use biological science and technology t...
MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) Reaches New 1-Year High Following Analyst Upgrade
Avalo Therapeutics (NASDAQ:AVTX) Sets New 52-Week High Following Analyst Upgrade...
MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) Price Target Raised to $58.00
BTIG Research upped their target price on shares of Avalo Therapeutics from $40.00 to $58.00 and gave the stock a 'buy' rating in a research report on Wednesday...
MarketBeat
Avalo Therapeutics Stock Jumps 33% In Pre-Market Session: Here's Why
Avalo Therapeutics Inc. rises sharply in pre-market trading following a Phase 2 trial win and a $375 million offering.read more...
Benzinga
Avalo Therapeutics (AVTX) to Release Earnings on Monday
Avalo Therapeutics (NASDAQ:AVTX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-avalo-therapeutics-inc-stock...
MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $111,886.11 in Stock
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) CFO Christopher Ryan Sullivan sold 8,457 shares of the company's stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $13.23, for a total value of $111,886.11. Following the completion of the sale, the...
MarketBeat
Christopher Ryan Sullivan Sells 8,458 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) CFO Christopher Ryan Sullivan sold 8,458 shares of Avalo Therapeutics stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $13.09, for a total transaction of $110,715.22. Following the completion of the...
MarketBeat
Moody Aldrich Partners LLC Buys Shares of 133,231 Avalo Therapeutics, Inc. $AVTX
Moody Aldrich Partners LLC bought a new position in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 133,231 shares of the c...
MarketBeat
<
1
2
...
>